Our present study suggested that β-amyloid deposition and associated neuronal pathologies are reduced in APP/PS1 model mice carrying the AD-protective PLCγ2-P522R variant as a result of increased microglial activation and clearance of β-amyloid deposits while suppressing their proinflammatory phenotype. Here, PLCG2 is linked to Alzheimer disease.